DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">

(April 24, 2007) Dr. David Gorenstein: "Thioaptamers in Proteomics Diagnostics and Therapeutics for Nanobiodefense" — Alliance for NanoHealth
 
 
You are here: Home Events Past Events ANH Seminar Series (April 24, 2007) Dr. David Gorenstein: "Thioaptamers in Proteomics Diagnostics and Therapeutics for Nanobiodefense"
Document Actions

(April 24, 2007) Dr. David Gorenstein: "Thioaptamers in Proteomics Diagnostics and Therapeutics for Nanobiodefense"

What ANH Breakfast Series
When April 24, 2007
from 12:00 pm to 01:30 pm
Where Beth Robertson Auditorium, Fayez S. Sarofim Research Building (IMM Building, 1825 Pressler Street)
Contact Name Dr. Jason Sakamoto
Contact Email
Contact Phone 713-500-2466
Add event to calendar vCal
iCal

The Alliance for NanoHealth is proud to announce the next ANH Lunch Meeting on April 24, 2007. The University of Texas Medical Branch's Dr. David Gorenstein will be featured as the event’s keynote speaker. You are cordially invited to attend this lunch session and encouraged to participate in the networking reception. Admission is free and open to the Texas Medical Center Community and Regional Academic Institutions.

David GorensteinBio:

Dr. David Gorenstein is Associate Dean for Research, School of Medicine, UTMB and the Charles Marc Pomerat Distinguished Professor in the Departments of Biochemistry & Molecular Biology and Neurosciences & Cell Biology. He is Associate Director of the new Institute for Clinical and Translational Research and is a member of the Sealy Center for Structural Biology and the Center for Biodefense and Emerging Infectious Diseases at UTMB. He previously served as the founding Director of the Sealy Center for Structural Biology, UTMB and serves as Director of the Gulf Coast Consortium in Magnetic Resonance, a shared facility which includes UTMB, Rice, Baylor College of Medicine, U. Houston, U. Texas Health Sciences Center, Houston, U. Texas M.D. Anderson Cancer Center and Dow Chemical. He has over 38 years experience in drug design, protein chemistry (and more recently proteomics and nanomedicine) as well as the development of biophysical applications of NMR spectroscopy to probe the detailed structure and dynamics of biological molecules with over 230 publications.

Dr. Gorenstein received a bachelors degree in chemistry from the Massachusetts Institute of Technology and a masters degree and doctorate in chemistry from Harvard University. Before coming to UTMB, he held faculty positions in the Departments of Chemistry at the University of Illinois at Chicago and Purdue University. He has received a number of awards, including Guggenheim (to UCSF) and senior Fulbright (to Oxford U., England) fellowships and election as Fellow to the AAAS. More recently he has developed novel technologies in proteomics diagnostics and therapeutics with applications to nanomedicine. Dr. Gorenstein holds over 3 dozen patents (awarded and pending) on the synthesis of dithiophosphate oligonucleotide analogues and thiophosphate aptamer (“thioaptamers”) combinatorial selection technologies, many of which have been licensed to AptaMed and AM Biotechnologies, Galveston companies he founded. Dr. Gorenstein has been more recently supported on NIH and DARPA-funded projects which provided for the development of the thioaptamer technologies as countermeasures and diagnostics in biodefense. He is also P.I. on a currently funded NIAID Biodefense Proteomics U01 Collaboratory grant (with Ciphergen) that is developing thioaptamer chip-based proteomics diagnostics technologies, also as part of a NHLBI Proteomics Center at UTMB.

     
 
« November 2008 »
Su Mo Tu We Th Fr Sa
1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30